Business Wire

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...
Nasdaq

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase ...

Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editing-based therapy, in newborn males with neonatal onset Ornithine ...
Nasdaq

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC ...

- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no ...
Seeking Alpha

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Virtual KOL Presentation at 12:00 p.m. ET Today SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicines company focused on the development of ...